Drug
Bepotastine clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
Tanabe Pharma Corporation (1) · Asan Medical Center (1) · Hom, Milton M., OD, FAAO (1)
Related medicines
As reviewed, each with the page that says it.
- One of Histamine Antagonists source
Studies
Open first, then newest update. How each study uses bepotastine is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic RhinitisCompletedPhase 3Tanabe Pharma CorporationNCT01425632Written as TAU-284
- Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic RhinitisCompletedPhase 4Asan Medical CenterNCT04877678Written as Bepotastine
- Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact LensesStatus unknownPhase 4Hom, Milton M., OD, FAAONCT01337557Written as Bepotastine
Codes
What other systems call bepotastine · ClinicalTrials.gg INT004020
- MeSH (NLM) C108476bepotastineOne source NLM
- UNII (FDA) HYD2U48IASBEPOTASTINEConfirmed FDA, NLM, Wikidata
- RxNorm 863035Confirmed FDA, Wikidata
- Wikidata Q4890915bepotastineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77431BepotastineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C108476 | bepotastine | One source NLM |
| UNII (FDA) | HYD2U48IAS | BEPOTASTINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 863035 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4890915 | bepotastine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77431 | Bepotastine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.